Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)

Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)

Background Monotherapy with immune checkpoint blockade is ineffective for patients (pts) with microsatellite stable (MSS) metastatic colorectal cancer (mCRC). This study investigates whether the combination of trametinib (T) with durvalumab (D) can alter the immune tumor microenvironment (TME) by su...

Full description

Bibliographic Details
Main Authors: Ignacio I Wistuba, Andrew Futreal, Xuemei Wang, Arvind Dasari, Cathy Eng, Scott Kopetz, Edwin R Parra, Cara L Haymaker, Eduardo Vilar, Robert A Wolff, Kanwal Raghav, Michael J Overman, Younghee Lee, Benny Johnson, Luisa Maren Solis Soto, Jane V Thomas, Van K Morris, Bryan K Kee, Christine M Parseghian, Daniele Lorenzini, Caddie Laberiano-Fernandez, Anuj Verma, Wenhua Lang
Format: Article
Language:English
Published: BMJ Publishing Group 2022-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/8/e005332.full

Internet

https://jitc.bmj.com/content/10/8/e005332.full

Similar Items